Healthcare Services

Acute Renal Failure (ARF) Market Growth Forecast With Analysis Of Industry Progress Through 2030

May 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Forecasted Market Size Figures For The Acute Renal Failure (ARF) Market In 2026 And 2030?

The acute renal failure (arf) market size has shown strong growth recently. It is forecast to increase from $6.6 billion in 2025 to $7.14 billion in 2026, at a compound annual growth rate (CAGR) of 8.3%. This historical growth can be linked to the rising prevalence of hypertension and diabetes, expanding hospital-based renal care, a lack of awareness regarding early arf symptoms, the continued adoption of conventional dialysis methods, and enhancements in hospital infrastructure.

The market size for acute renal failure (arf) is projected to experience substantial expansion in the coming years. It is anticipated to reach $9.71 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.0%. This growth during the forecast period can be attributed to the development of novel nephroprotective drugs, the integration of AI-based diagnostics, the expansion of home healthcare services, an increasing geriatric population, and rising investment in renal disease research. Major trends expected in the forecast period include a rising adoption of advanced dialysis and renal support therapies, an increasing focus on the early diagnosis of acute kidney injury, a growth in the use of nephroprotective drug therapies, an expansion of imaging and biopsy-based diagnostic techniques, and an increasing preference for home healthcare management for arf patients.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21083&type=smp

What Important Drivers Are Powering The Acute Renal Failure (ARF) Market Growth?

The expanding occurrence of chronic kidney diseases is anticipated to drive the acute renal failure (ARF) market’s growth moving ahead. Chronic kidney disease (CKD) denotes a persistent ailment where kidney damage impairs proper blood filtration. The rising prevalence of chronic kidney disease (CKD) stems from increasing global rates of diabetes, hypertension, obesity, an aging demographic, and lifestyle influences. Acute renal failure, marked by an abrupt decline in kidney function, can significantly initiate or worsen chronic kidney disease by inflicting permanent damage to kidney tissues, compromising filtration effectiveness, and elevating the likelihood of ongoing, prolonged kidney dysfunction if not appropriately managed. For example, a report released by Kidney Research UK, a UK-based non-profit organization, in June 2023 indicated that around 7.2 million individuals in the UK currently suffer from chronic kidney disease, accounting for more than 10% of the population. Of these, 3.25 million are in advanced stages of the condition, whereas another 3.9 million are in its initial phases. Projections indicate that by 2033, the count of people impacted by chronic kidney disease will climb to 7.61 million. Consequently, the growing occurrence of chronic kidney diseases is fueling the expansion of the acute renal failure (ARF) market.

How Is The Acute Renal Failure (ARF) Market Examined Through Segment Analysis?

The acute renal failure (arf) market covered in this report is segmented –

1) By Disease Type: Prerenal Acute Renal Failure, Renal Acute Renal Failure, Postrenal Acute Renal Failure

2) By Drug Type: Diuretics, Vasopressors, Erythropoiesis-Stimulating Agents (ESAS), Phosphate Binders, Calcium and Vitamin D Supplements, Antibiotics, Other Drugs

3) By Route of Administration: Oral, Intravenous

4) By End-Users: Clinics, Hospitals, Others End-Users

Subsegments:

1) By Prerenal Acute Renal Failure: Hypovolemia, Decreased Cardiac Output, Renal Artery Stenosis

2) By Renal Acute Renal Failure: Acute Tubular Necrosis, Glomerulonephritis, Interstitial Nephritis

3) By Postrenal Acute Renal Failure: Obstructive Uropathy, Bladder Outlet Obstruction, Kidney Stones

Which Trends Are Guiding The Development Of The Acute Renal Failure (ARF) Market?

Leading firms within the acute renal failure (ARF) market are concentrating on securing regulatory authorizations for their pharmaceutical products to broaden their influence and solidify their standing in managing severe acute kidney injury (AKI). Such approvals signify official permission granted by governmental or overseeing agencies for the commercialization and public application of medications, medical apparatus, or therapies. Illustratively, during February 2024, CalciMedica., a clinical-stage biopharmaceutical firm based in the US, secured FDA endorsement for an Investigational New Drug (IND) application, allowing a Phase 2 trial of Auxora. This trial aims to assess Auxora’s effectiveness in addressing severe acute kidney injury (AKI) linked to acute hypoxemic respiratory failure (AHRF), a condition known for its significant mortality. The KOURAGE trial, structured as a randomized, double-blind, placebo-controlled investigation, plans to recruit approximately 150 patients presenting with Stage 2 and 3 acute kidney injury (AKI) alongside acute hypoxemic respiratory failure (AHRF). It will gauge Auxora’s effectiveness across five daily doses by measuring the duration patients remain alive without requiring ventilators or dialysis for up to 30 days following treatment.

Which Firms Are Competing In The Acute Renal Failure (ARF) Market?

Major companies operating in the acute renal failure (arf) market are Pfizer Inc, Novartis AG, Baxter International Inc, Fresenius Medical Care AG and Co KGaA, Medtronic plc, Asahi Kasei Corporation, Astellas Pharma Inc, NIKKISO Co Ltd, NIPRO Corporation, Quark Pharmaceuticals Inc, AM Pharma BV, Sentien Biotechnologies, Angion Biomedica Corp, Alloksys Life Sciences BV, Theravance Biopharma, Kissei Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, B Braun Melsungen AG, Chiesi Farmaceutici SpA, Takeda Pharmaceutical Company Limited

Access The Complete Acute Renal Failure (ARF) Market Report:

https://www.thebusinessresearchcompany.com/report/acute-renal-failure-arf-global-market-report

Which Region Stands As The Largest Contributor To The Acute Renal Failure (ARF) Market?

North America was the largest region in the acute renal failure (ARF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute renal failure (arf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acute Renal Failure (ARF) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21083&type=smp

Browse Through More Reports Similar to the Global Acute Renal Failure (ARF) Market 2026, By The Business Research Company

Kidney Disease Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Kidney Dialysis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-dialysis-global-market-report

Continuous Renal Replacement Therapy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/continuous-renal-replacement-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795